Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02500927
Recruitment Status : Terminated (Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.)
First Posted : July 17, 2015
Last Update Posted : October 23, 2018
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

Condition or disease Intervention/treatment Phase
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations Drug: ASP8273 Capsules Drug: ASP8273 Capsules A Phase 2

Detailed Description:
This study consists of a single-dose period (Cycle 0 lasting 3 days) and a multiple-dose period (from Cycle 1 onwards, each cycle lasting 21 days). To compare the PK between ASP8273 Capsules and ASP8273 Capsules A, enrolled subjects will receive a single oral dose of ASP8273 Capsules A on Day 1 of Cycle 0 in the single-dose period and will then be observed for 3 days (including the day of dosing). In the multiple-dose period, subjects will receive multiple oral doses of ASP8273 Capsules during each cycle lasting 21 days. From the viewpoint of PK comparison (bioavailability [BA] evaluation) between ASP8273 Capsules and ASP8273 Capsules A, data from approximately 15 subjects are sufficient for the evaluation. Therefore, if PK data of approximately 15 subjects included in BA evaluation are obtained and the sponsor judges that further acquisition of PK data is not necessary, the single-dose period will not be conducted in subjects who are enrolled thereafter (subjects not included in BA evaluation). Subjects will continue to receive treatment with ASP8273 until they meet the discontinuation criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of ASP8273 — An Open-Label, Study of the Oral Administration of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-NaïvePatients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Actual Study Start Date : June 25, 2015
Actual Primary Completion Date : June 9, 2017
Actual Study Completion Date : June 9, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Tyrosine

Arm Intervention/treatment
Experimental: ASP8273 group
Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
Drug: ASP8273 Capsules
oral

Drug: ASP8273 Capsules A
oral




Primary Outcome Measures :
  1. Safety assessed by AEs [ Time Frame: Up to 18 months ]
  2. Safety assessed by Laboratory tests [ Time Frame: Up to 18 months ]
  3. Safety assessed by Vital signs [ Time Frame: Up to 18 months ]
  4. Safety assessed by Percutaneous oxygen saturation (SpO2) [ Time Frame: Up to 18 months ]
  5. Safety assessed by Body weight [ Time Frame: Up to 18 months ]
  6. Safety assessed by 12-lead ECG [ Time Frame: Up to 18 months ]
    ECG: Electrocardiogram

  7. Safety assessed by Ophthalmologic examination [ Time Frame: Up to 18 months ]
  8. Safety assessed by Chest X-ray examination [ Time Frame: Up to 18 months ]
  9. Safety assessed by Chest computed tomography (CT) examination [ Time Frame: Up to 18 months ]
  10. Safety assessed by ECOG Performance Status [ Time Frame: Up to 18 months ]

Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: Up to 18 months ]
    The overall response rate is defined as the proportion of subjects whose best overall response is rated as Complete response (CR) or Partial Response (PR)among all analyzed subjects

  2. Disease control rate [ Time Frame: Up to 18 months ]
    The disease control rate is defined as the proportion of subjects whose best overall response is rated as Complete response (CR), Partial Response (PR), or Stable disease (SD) among all analyzed subjects

  3. Plasma concentrations of unchanged ASP8273 [ Time Frame: Up to Day1 of Cycle 3 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
  • Patients with a histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC.
  • Patients confirmed to have the deletion of exon 19 (del ex19), L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients at the study site who are documented to have any of the above-stated EGFR activating mutations can be enrolled in the study).
  • Patients with a life expectancy ≥ 12 weeks based on the principal investigator's/subinvestigator's judgment.
  • Patients who meet all of the following requirements for laboratory tests within 7 days before enrollment. When 2 or more test results for a single parameter are found within the specified period, the last data before enrollment should be used for assessment.

    • Neutrophil count: ≥ 1,500/mm3
    • Platelet count: ≥ 75,000/mm3
    • Hemoglobin: ≥ 9 g/dL
    • Serum creatinine: < 1.5 mg/dL
    • Total bilirubin (TBL): < 1.5 × the upper limit of normal (ULN) at the site (this does not apply to patients with Gilbert syndrome)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): < 2.5 ×the ULN at the site
  • Patients who meet all the following requirements for prior treatment for NSCLC:

    • Patients who have not received previous treatment with EGFR-TKIs*1 *1: Erlotinib, gefitinib, afatinib, and EGFR-TKIs under clinical investigation (e.g.,neratinib, dacomitinib). EGFR-TKIs that can inhibit EGFR with the T790Mmutation (e.g., ASP8273, CO-1686, AZD9291) are also included.
  • Patients who have not received more than one regimen of previous drug treatment (however, this does not include preoperative or postoperative therapies used within at least a 6-month interval after the last dose of the treatment).
  • Patients who have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Exclusion Criteria:

  • Patients with persistent clinical evidence of previous antitumor treatment-related toxicity ≥ Grade 2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCI CTCAE v4.0 - JCOG) (except alopecia).
  • Patients with a history of or concurrent interstitial lung disease.
  • Patients who have received previous treatment with intended antitumor effects or treatment with another investigational drug/medical device within 14 days before the start of the study treatment.
  • Patients who have received transfusion or hematopoietic growth factor therapy within 14 days prior to the start of the study treatment.
  • Patients who have received oral or intravenous corticosteroids within 7 days prior to the start of the study treatment (except to treat or prevent an allergic reaction).
  • Patients who are scheduled to undergo a surgical procedure during the course of the study or the patient still has an unhealed wound after previous surgery.
  • Patients with a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (anti-HCV).
  • Patients with a known history of a positive test for human immunodeficiency virus (HIV) infection.
  • Patients with symptomatic central nervous system (CNS) lesions.
  • Patients with a known history of serious drug hypersensitivity.
  • Patients with evidence of active infection requiring systemic drug therapy within 14 days prior to the start of the study treatment.
  • Patients who have received strong CYP3A inhibitors within 9 days prior to the start of the study treatment (for itraconazole, within 14 days prior to the start of the study treatment).
  • Patients who have received moderate CYP3A inhibitors within 9 days prior to the start of the study treatment (only for subjects included in BA evaluation).
  • Patients who have received strong or moderate CYP3A inducers within 14 days prior to the start of the study treatment (only for subjects included in BA evaluation).
  • Patients with prolongation of the QTc interval (male: ≥ 451 ms, female: ≥ 471 ms) on the 12-lead electrocardiogram (ECG) in the screening period.
  • Patients with cardiac arrhythmias requiring treatment.
  • Patients with Class 3 or 4 New York Heart Association (NYHA) congestive heart failure.
  • Patients with a history of acute coronary syndrome, myocardial infarction, or cerebrovascular accident within 6 months prior to enrollment.
  • Patients with a history of or concurrent active peptic ulcer disease or gastrointestinal bleeding within 3 months prior to enrollment.
  • Patients with corneal disease ≥ Grade 2.
  • Patients with difficulty to take oral medication, or any gastrointestinal malfunction or inflammatory bowel disease that is considered to affect drug absorption.
  • Patients with active multiple cancers (simultaneous multiple cancers).
  • Patients with other conditions ineligible for participation in the study based on the principal investigator's/sub-investigator's judgment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02500927


Locations
Layout table for location information
Japan
Site: 5
Fukuoka, Japan
Site: 9
Hiroshima, Japan
Site: 8
Hyogo, Japan
Site: 7
Kanagawa, Japan
Site: 11
Miyagi, Japan
Site: 1
Miyagi, Japan
Site: 10
Nagoya, Japan
Site: 4
Okayama, Japan
Site: 3
Osaka, Japan
Site: 6
Osaka, Japan
Site: 2
Tokyo, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Layout table for investigator information
Study Director: Medical Director Astellas Pharma Inc
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT02500927    
Other Study ID Numbers: 8273-CL-0202
First Posted: July 17, 2015    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Keywords provided by Astellas Pharma Inc:
ASP8273
Non-Small Cell Lung Cancer
EGFR Tyrosine Kinase Inhibitor
EGFR Mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Naquotinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action